Boehringer Ingelheim Announces Interim Results on Adalimumab Biosimilar Candidate BI695501

Today, Boehringer Ingelheim announced the 24-week results from the Phase III VOLTAIRE®-RA study, comparing the adalimumab biosimilar candidate BI 695501 to Abbvie’s Humira® in patients with moderate- to severely-active rheumatoid arthritis.  According to BI, the results indicate that BI 695501 has similar efficacy, safety, and immunogenicity as Humira® in these patients.  The results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.